Highlights & Basics
- Guillain-Barre syndrome (GBS) is an acute inflammatory polyneuropathy that is classified according to symptoms and divided into axonal and demyelinating forms.
- Two-thirds of patients have a history of gastroenteritis or influenza-like illness weeks before onset of neurologic symptoms. The acute infectious illness is usually viral, but sometimes bacterial.
- Approximately 20% to 30% of patients with GBS will develop respiratory muscle weakness requiring ventilation.
- Neurophysiology is confirmatory and is abnormal in most patients, even early in the disease.
- Lumbar puncture is useful, and the classic finding is elevated protein with normal cell count (albuminocytologic dissociation).
Quick Reference
History & Exam
Key Factors
Other Factors
Diagnostics Tests
Treatment Options
Definition
Epidemiology
Etiology
Pathophysiology
Citations
van Doorn PA, Van den Bergh PYK, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of Guillain-Barré syndrome. Eur J Neurol. 2023 Dec;30(12):3646-74.[Abstract][Full Text]
Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol. 2019 Nov;15(11):671-83.[Abstract][Full Text]
Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2014 Sep 19;(9):CD002063.[Abstract][Full Text]
Hughes RA, Wijdicks EF, Barohn R, et al. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2003 Sep 23;61(6):736-40.[Abstract][Full Text]
1. Hadden RD, Hughes RA. Management of inflammatory neuropathies. J Neurol Neurosurg Psychiatry. 2003 Jun;74(suppl 2):ii9-14.[Abstract][Full Text]
2. Hiraga A, Mori M, Ogawara K, et al. Recovery patterns and long term prognosis for axonal Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 2005 May;76(5):719-22.[Abstract][Full Text]
3. Guillain G, Barré JA, Strohl A. Radiculoneuritis syndrome with hyperalbuminosis of cerebrospinal fluid without cellular reaction. Notes on clinical features and graphs of tendon reflexes. 1916 [in French]. Ann Med Interne (Paris). 1999 Jan;150(1):24-32.[Abstract]
4. Asbury AK, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. Medicine (Baltimore). 1969 May;48(3):173-215.[Abstract]
5. Counotte MJ, Meili KW, Taghavi K, et al. Zika virus infection as a cause of congenital brain abnormalities and Guillain-Barré syndrome: a living systematic review. F1000Res. 2019 Aug 14;8:1433.[Abstract][Full Text]
6. Ralapanawa DM, Kularatne SA, Jayalath WA. Guillain-Barre syndrome following dengue fever and literature review. BMC Res Notes. 2015 Nov 27;8:729.[Abstract][Full Text]
7. Oehler E, Fournier E, Leparc-Goffart I, et al. Increase in cases of Guillain-Barré syndrome during a Chikungunya outbreak, French Polynesia, 2014 to 2015. Euro Surveill. 2015;20(48):30079.[Abstract]
8. Simon O, Billot S, Guyon D, et al. Early Guillain-Barré syndrome associated with acute dengue fever. J Clin Virol. 2016 Apr;77:29-31.[Abstract]
9. Cerny T, Schwarz M, Schwarz U, et al. The range of neurological complications in chikungunya fever. Neurocrit Care. 2017 Dec;27(3):447-57.[Abstract][Full Text]
10. Martos-Benítez FD, Betancourt-Plaza I, Osorio-Carmenates I, et al. Neurological performance and clinical outcomes related to patients with oropouche-associated Guillain-Barré syndrome. J Peripher Nerv Syst. 2025 Mar;30(1):e12683.[Abstract]
11. Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med. 2012 Jun 14;366(24):2294-304.[Abstract]
12. Bickerstaff ER. Brain-stem encephalitis; further observations on a grave syndrome with benign prognosis. Br Med J. 1957 Jun 15;1(5032):1384-7.[Abstract][Full Text]
13. Mericle RA, Triggs WJ. Treatment of acute pandysautonomia with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry. 1997 May;62(5):529-31.[Abstract][Full Text]
14. Anzai T, Uematsu D, Takahashi K, et al. Guillain-Barré syndrome with bilateral tonic pupils. Intern Med. 1994 Apr;33(4):248-51.[Abstract][Full Text]
15. van Doorn PA, Van den Bergh PYK, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of Guillain-Barré syndrome. Eur J Neurol. 2023 Dec;30(12):3646-74.[Abstract][Full Text]
16. Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome. Lancet. 2021 Mar 27;397(10280):1214-28.[Abstract]
17. Bao J, Nunez C, Elliott E, et al. Acute flaccid paralysis in Australian children from 2007 to 2017. Neuroepidemiology. 2023;57(1):25-34.[Abstract]
18. Webb AJ, Brain SA, Wood R, et al. Seasonal variation in Guillain-Barré syndrome: a systematic review, meta-analysis and Oxfordshire cohort study. J Neurol Neurosurg Psychiatry. 2015 Nov;86(11):1196-201.[Abstract][Full Text]
19. Xu L, Zhao C, Bao Y, et al. Variation in worldwide incidence of Guillain-Barré syndrome: a population-based study in urban China and existing global evidence. Front Immunol. 2024;15:1415986.[Abstract][Full Text]
20. GBD 2021 Nervous System Disorders Collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024 Apr;23(4):344-81.[Abstract][Full Text]
21. Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol. 2019 Nov;15(11):671-83.[Abstract][Full Text]
22. Doets AY, Verboon C, van den Berg B, et al. Regional variation of Guillain-Barré syndrome. Brain. 2018 Oct 1;141(10):2866-77.[Abstract][Full Text]
23. Bragazzi NL, Kolahi AA, Nejadghaderi SA, et al. Global, regional, and national burden of Guillain-Barré syndrome and its underlying causes from 1990 to 2019. J Neuroinflammation. 2021 Nov 11;18(1):264.[Abstract][Full Text]
24. Wachira VK, Farinasso CM, Silva RB, et al. Incidence of Guillain-Barré syndrome in the world between 1985 and 2020: a systematic review. Glob Epidemiol. 2023 Dec;5:100098.[Abstract][Full Text]
25. Bae JS, Yuki N, Kuwabara S, et al. Guillain-Barré syndrome in Asia. J Neurol Neurosurg Psychiatry. 2014 Aug;85(8):907-13.[Abstract]
26. Mitsui Y, Kusunoki S, Arimura K, et al. A multicentre prospective study of Guillain-Barré syndrome in Japan: a focus on the incidence of subtypes. J Neurol Neurosurg Psychiatry. 2015 Jan;86(1):110-4.[Abstract]
27. Barbi L, Coelho AVC, Alencar LCA, et al. Prevalence of Guillain-Barré syndrome among Zika virus infected cases: a systematic review and meta-analysis. Braz J Infect Dis. 2018 Mar-Apr;22(2):137-41.[Abstract][Full Text]
28. Capasso A, Ompad DC, Vieira DL, et al. Incidence of Guillain-Barré Syndrome (GBS) in Latin America and the Caribbean before and during the 2015-2016 Zika virus epidemic: A systematic review and meta-analysis. PLoS Negl Trop Dis. 2019 Aug;13(8):e0007622.[Abstract][Full Text]
29. Cardona-Ospina JA, Henao-SanMartin V, Acevedo-Mendoza WF, et al. Fatal Zika virus infection in the Americas: A systematic review. Int J Infect Dis. 2019 Nov;88:49-59.[Abstract][Full Text]
30. Censi S, Bisaccia G, Gallina S, et al. Guillain-Barré syndrome and SARS-CoV-2 infection: a systematic review and meta-analysis on a debated issue and evidence for the 'Italian factor'. Eur J Neurol. 2024 Feb;31(2):e16094.[Abstract][Full Text]
31. Palaiodimou L, Stefanou MI, Katsanos AH, et al. Prevalence, clinical characteristics and outcomes of Guillain-Barré syndrome spectrum associated with COVID-19: a systematic review and meta-analysis. Eur J Neurol. 2021 Oct;28(10):3517-29.[Abstract]
32. Keddie S, Pakpoor J, Mousele C, et al. Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome. Brain. 2021 Mar 3;144(2):682-93.[Abstract][Full Text]
33. Censi S, Bisaccia G, Gallina S, et al. Guillain-Barré syndrome and COVID-19 vaccination: a systematic review and meta-analysis. J Neurol. 2024 Mar;271(3):1063-71.[Abstract][Full Text]
34. Gligorov M, Lebrun-Vignes B, Masmoudi K, et al. Vaccines and the risk of Guillain-Barré syndrome: a French pharmacovigilance analysis. Therapie. 2025 Sep-Oct;80(5):580-8.[Abstract][Full Text]
35. Geleijns K, Emonts M, Laman JD, et al. Genetic polymorphisms of macrophage-mediators in Guillain-Barré syndrome. J Neuroimmunol. 2007 Oct;190(1-2):127-30.[Abstract]
36. Zhang L, Liu L, Li H, et al. Association of CD1 and FcγR gene polymorphisms with Guillain-Barré syndrome susceptibility: a meta-analysis. Neurol Sci. 2018 Dec;39(12):2141-9.[Abstract]
37. Leonhard SE, van der Eijk AA, Andersen H, et al. An international perspective on preceding infections in Guillain-Barré syndrome: the IGOS-1000 cohort. Neurology. 2022 Sep 20;99(12):e1299-313.[Abstract]
38. Shui IM, Rett MD, Weintraub E, et al. Guillain-Barré syndrome incidence in a large United States cohort (2000-2009). Neuroepidemiology. 2012;39(2):109-15.[Abstract]
39. Guillain-Barré Syndrome Study Group. Guillain-Barré syndrome: an Italian multicentre case-control study. Neurol Sci. 2000 Aug;21(4):229-34.[Abstract]
40. Poropatich KO, Walker CL, Black RE. Quantifying the association between Campylobacter infection and Guillain-Barré syndrome: a systematic review. J Health Popul Nutr. 2010 Dec;28(6):545-52.[Abstract][Full Text]
41. Schwerer B. Antibodies against gangliosides: a link between preceding infection and immunopathogenesis of Guillain-Barré syndrome. Microbes Infect. 2002 Mar;4(3):373-84.[Abstract]
42. Visser LH, Van der Meché FG, Van Doorn PA, et al. Guillain-Barré syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-Barré Study Group. Brain. 1995 Aug;118(Pt 4):841-7.[Abstract]
43. Griffin JW, Li CY, Ho TW, et al. Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann Neurol. 1996 Jan;39(1):17-28.[Abstract]
44. Almqvist J, Granberg T, Tzortzakakis A, et al. Neurological manifestations of coronavirus infections - a systematic review. Ann Clin Transl Neurol. 2020 Oct;7(10):2057-71.[Abstract][Full Text]
45. Hasan I, Saif-Ur-Rahman KM, Hayat S, et al. Guillain-Barré syndrome associated with SARS-CoV-2 infection: A systematic review and individual participant data meta-analysis. J Peripher Nerv Syst. 2020 Dec;25(4):335-43.[Abstract][Full Text]
46. Langmuir AD, Bregman DJ, Kurland LT, et al. An epidemiologic and clinical evaluation of Guillain-Barré syndrome reported in association with the administration of swine influenza vaccines. Am J Epidemiol. 1984 Jun;119(6):841-79.[Abstract]
47. Hemachudha T, Griffin DE, Chen WW, et al. Immunologic studies of rabies vaccination-induced Guillain-Barré syndrome. Neurology. 1988 Mar;38(3):375-8.[Abstract]
48. D'alò GL, Zorzoli E, Capanna A, et al. Frequently asked questions on seven rare adverse events following immunization. J Prev Med Hyg. 2017 Mar;58(1):E13-E26.[Abstract][Full Text]
49. Sanz Fadrique R, Martín Arias L, Molina-Guarneros JA, et al. Guillain-Barré syndrome and influenza vaccines: current evidence. Rev Esp Quimioter. 2019 Aug;32(4):288-95.[Abstract][Full Text]
50. Anastassopoulou C, Panagiotopoulos AP, Ferous S, et al. RSV vaccines and Guillain-Barré syndrome: Insights into an emerging concern. Vaccine. 2025 Aug 13;61:127338.[Abstract]
51. Hause AM, Moro PL, Baggs J, et al. Early safety findings among persons aged ≥60 years who received a respiratory syncytial virus vaccine - United States, May 3, 2023-April 14, 2024. MMWR Morb Mortal Wkly Rep. 2024 May 30;73(21):489-94.[Full Text]
52. Fry SE, Terebuh P, Kaelber DC, et al. Effectiveness and safety of respiratory syncytial virus vaccine for US adults aged 60 years or older. JAMA Netw Open. 2025 May 1;8(5):e258322.[Abstract][Full Text]
53. Centers for Disease Control and Prevention. Vaccine safety: meningococcal vaccine safety. Dec 2024 [internet publication].[Full Text]
54. Martín Arias LH, Sanz R, Sáinz M, et al. Guillain-Barré syndrome and influenza vaccines: a meta-analysis. Vaccine. 2015 Jul 17;33(31):3773-8.[Abstract]
55. Malkki H. CNS infections: Zika virus infection could trigger Guillain-Barré syndrome. Nat Rev Neurol. 2016 Apr;12(4):187.[Abstract][Full Text]
56. Anaya JM, Ramirez-Santana C, Salgado-Castaneda I, et al. Zika virus and neurologic autoimmunity: the putative role of gangliosides. BMC Med. 2016 Mar 21;14:49.[Abstract][Full Text]
57. Centers for Disease Control and Prevention. Oropouche: clinical overview of Oropouche virus disease. Nov 2025 [internet publication].[Full Text]
58. Astaras C, de Micheli R, Moura B, et al. Neurological adverse events associated with immune checkpoint inhibitors: diagnosis and management. Curr Neurol Neurosci Rep. 2018 Feb 1;18(1):3.[Abstract]
59. Ellithi M, Elsallab M, Lunning MA, et al. Neurotoxicity and rare adverse events in BCMA-directed CAR T cell therapy: a comprehensive analysis of real-world FAERS data. Transplant Cell Ther. 2025 Feb;31(2):71.e1-14.[Abstract]
60. Puwanant A, Isfort M, Lacomis D, et al. Clinical spectrum of neuromuscular complications after immune checkpoint inhibition. Neuromuscul Disord. 2019 Feb;29(2):127-33.[Abstract]
61. Carr AS, Vonberg FW, Koay S, et al. Neurological complications of immune checkpoint inhibitors: a practical guide. Pract Neurol. 2025 Mar 14;25(2):116-26.[Abstract][Full Text]
62. Li Y, Zhang X, Zhao C. Guillain-Barré Syndrome-like polyneuropathy associated with immune checkpoint inhibitors: a systematic review of 33 cases. Biomed Res Int. 2021;2021:9800488.[Abstract][Full Text]
63. Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2017 Feb 27;(2):CD001798.[Abstract][Full Text]
64. Hughes RA, Hadden RD, Gregson NA, et al. Pathogenesis of Guillain-Barré syndrome. J Neuroimmunol. 1999 Dec;100(1-2):74-97.[Abstract]
65. Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2014 Sep 19;(9):CD002063.[Abstract][Full Text]
66. Ogawara K, Kuwabara S, Mori M, et al. Axonal Guillain-Barre syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol. 2000 Oct;48(4):624-31.[Abstract]
67. Kuijf ML, Godschalk PC, Gilbert M, et al. Origin of ganglioside complex antibodies in Guillain-Barré syndrome. J Neuroimmunol. 2007 Aug;188(1-2):69-73.[Abstract]
68. Shu XM, Cai FC, Zhang XP. Carbohydrate mimicry of Campylobacter jejuni lipooligosaccharide is critical for the induction of anti-GM1 antibody and neuropathy. Muscle Nerve. 2006 Feb;33(2):225-31.[Abstract]
69. Yuki N, Susuki K, Koga M, et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barré syndrome. Proc Natl Acad Sci USA. 2004 Aug 3;101(31):11404-9.[Abstract][Full Text]
70. Brown WF, Feasby TE. Conduction block and denervation in Guillain-Barré polyneuropathy. Brain. 1984 Mar;107(Pt 1):219-39.[Abstract]
71. Hafer-Macko C, Hsieh ST, Li CY, et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol. 1996 Oct;40(4):635-44.[Abstract]
72. Griffin JW, Li CY, Macko C, et al. Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barré syndrome. J Neurocytol. 1996 Jan;25(1):33-51.[Abstract]
73. Safranek TJ, Lawrence DN, Kurland LT, et al. Reassessment of the association between Guillain-Barré syndrome and receipt of swine influenza vaccine in 1976-1977: results of a two-state study. Expert Neurology Group. Am J Epidemiol. 1991 May 1;133(9):940-51.[Abstract]
74. Ho TW, Hsieh ST, Nachamkin I, et al. Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection. Neurology. 1997 Mar;48(3):717-24.[Abstract]
75. McCarthy N, Giesecke J. Incidence of Guillain-Barré syndrome following infection with Campylobacter jejuni. Am J Epidemiol. 2001 Mar 15;153(6):610-4.[Abstract][Full Text]
76. Cao-Lormeau VM, Blake A, Mons S, et al. Guillain-Barré syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet. 2016 Apr 9;387(10027):1531-9.[Abstract][Full Text]
77. World Health Organization. Assessment and management of Guillain-Barré syndrome in the context of Zika virus infection: interim guidance. Aug 2016 [internet publication].[Full Text]
78. Public Health England. Guidance: Zika virus and Guillain-Barré syndrome. Aug 2017 [internet publication].[Full Text]
79. Zheng X, Yu L, Xu Q, et al. Guillain-Barre syndrome caused by hepatitis E infection: case report and literature review. BMC Infect Dis. 2018 Jan 23;18(1):50.[Abstract][Full Text]
80. Stevens O, Claeys KG, Poesen K, et al. Diagnostic challenges and clinical characteristics of hepatitis E virus-associated Guillain-Barré syndrome. JAMA Neurol. 2017 Jan 1;74(1):26-33.[Abstract][Full Text]
81. Liu H, Ma Y. Hepatitis E virus-associated Guillain-Barre syndrome: Revision of the literature. Brain Behav. 2020 Jan;10(1):e01496.[Abstract][Full Text]
82. Hughes CL, Yorio JT, Kovitz C, et al. Treatment decisions in a man with Hodgkin lymphoma and Guillian-Barré syndrome: a case report. J Med Case Rep. 2014 Dec 21;8:455.[Abstract][Full Text]
83. Al IO, Koç B, Bayram C, et al. Variant Guillain-Barré syndrome in a patient with Hodgkin lymphoma: AMSAN. Turk Pediatri Ars. 2018 Dec;53(4):263-6.[Abstract][Full Text]
84. Hiew FL, Rajabally YA. Malignancy in Guillain-Barré syndrome: A twelve-year single-center study. J Neurol Sci. 2017 Apr 15;375:275-8.[Abstract]
85. Vigliani MC, Magistrello M, Polo P, et al. Risk of cancer in patients with Guillain-Barré syndrome (GBS). A population-based study. J Neurol. 2004 Mar;251(3):321-6.[Abstract]
86. Hadden RD, Karch H, Hartung HP, et al; Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology. 2001 Mar 27;56(6):758-65.[Abstract]
87. Vidal JE, Guedes BF, Gomes HR, et al. Guillain-Barré syndrome spectrum as manifestation of HIV-related immune reconstitution inflammatory syndrome: case report and literature review. Braz J Infect Dis. 2022 May-Jun;26(3):102368.[Abstract][Full Text]
88. Wang Y, Yang J, Wen Y. The peculiarity of infection and immunity correlated with Guillain-Barré Syndrome in the HIV-infected population. J Clin Med. 2023 Jan 23;12(3):907.[Abstract][Full Text]
89. Asbury AK. New concepts of Guillain-Barré syndrome. J Child Neurol. 2000 Mar;15(3):183-91.[Abstract]
90. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol. 1990;27 suppl:S21-4.[Abstract]
91. Van der Meché FG, Van Doorn PA, Meulstee J, et al. Diagnostic and classification criteria for the Guillain-Barré syndrome. Eur Neurol. 2001;45(3):133-9.[Abstract]
92. Fokke C, van den Berg B, Drenthen J, et al. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014 Jan;137(pt 1):33-43.[Abstract]
93. Zaeem Z, Siddiqi ZA, Zochodne DW. Autonomic involvement in Guillain-Barré syndrome: an update. Clin Auton Res. 2019 Jun;29(3):289-99.[Abstract][Full Text]
94. Winer JB, Hughes RA, Anderson MJ, et al. A prospective study of acute idiopathic neuropathy. II. Antecedent events. J Neurol Neurosurg Psychiatry. 1988 May;51(5):613-8.[Abstract][Full Text]
95. Huang C, Zhang Y, Deng S, et al. Trauma-related Guillain-Barré syndrome: systematic review of an emerging concept. Front Neurol. 2020;11:588290.[Abstract][Full Text]
96. Wu X, Shen D, Li T, et al. Distinct clinical characteristics of pediatric Guillain-Barré syndrome: a comparative study between children and adults in northeast China. PLoS One. 2016 Mar 14;11(3):e0151611.[Abstract][Full Text]
97. Korinthenberg R, Trollmann R, Felderhoff-Müser U, et al. Diagnosis and treatment of Guillain-Barré syndrome in childhood and adolescence: an evidence- and consensus-based guideline. Eur J Paediatr Neurol. 2020 Mar;25:5-16.[Abstract]
98. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016 Aug 13;388(10045):717-27.[Abstract][Full Text]
99. Sakakibara R, Uchiyama T, Kuwabara S, et al. Prevalence and mechanism of bladder dysfunction in Guillain-Barré Syndrome. Neurourol Urodyn. 2009;28(5):432-7.[Abstract]
100. Teitelbaum JS, Borel CO. Respiratory dysfunction in Guillain-Barré syndrome. Clin Chest Med. 1994 Dec;15(4):705-14.[Abstract]
101. Ho TW, Mishu B, Li CY, et al. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 1995 Jun;118 ( Pt 3):597-605.[Abstract]
102. Hiraga A, Mori M, Ogawara K, et al. Differences in patterns of progression in demyelinating and axonal Guillain-Barré syndromes. Neurology. 2003 Aug 26;61(4):471-4.[Abstract]
103. Feasby TE, Gilbert JJ, Brown WF, et al. An acute axonal form of Guillain-Barre polyneuropathy. Brain. 1986 Dec;109(Pt 6):1115-26.[Abstract]
104. Teener JW. Miller Fisher's syndrome. Semin Neurol. 2012 Nov;32(5):512-6.[Abstract]
105. Mori M, Kuwabara S, Koga M, et al. IgG anti-GQ1b positive acute ataxia without ophthalmoplegia. J Neurol Neurosurg Psychiatry. 1999 Nov;67(5):668-70.[Abstract][Full Text]
106. Kaymakamzade B, Selcuk F, Koysuren A, et al. Pupillary involvement in Miller Fisher syndrome. Neuroophthalmology. 2013;37(3):111-5.[Abstract][Full Text]
107. Caccavale A, Mignemi L. Acute onset of a bilateral areflexical mydriasis in Miller-Fisher syndrome: a rare neuro-ophthalmologic disease. J Neuroophthalmol. 2000 Mar;20(1):61-2.[Abstract]
108. Mori M, Kuwabara S, Fukutake T, et al. Clinical features and prognosis of Miller Fisher syndrome. Neurology. 2001 Apr 24;56(8):1104-6.[Abstract]
109. Sekiguchi Y, Mori M, Misawa S, et al. How often and when Fisher syndrome is overlapped by Guillain-Barré syndrome or Bickerstaff brainstem encephalitis? Eur J Neurol. 2016 Jun;23(6):1058-63.[Abstract]
110. Overell JR, Hsieh ST, Odaka M, et al. Treatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and related disorders. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD004761.[Abstract][Full Text]
111. Odaka M, Yuki N, Yamada M, et al. Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barré syndrome. Brain. 2003 Oct;126(Pt 10):2279-90.[Abstract][Full Text]
112. Yuki N, Sato S, Tsuji S, et al. An immunologic abnormality common to Bickerstaff's brain stem encephalitis and Fisher's syndrome. J Neurol Sci. 1993 Aug;118(1):83-7.[Abstract]
113. Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet. 2005 Nov 5;366(9497):1653-66.[Abstract]
114. Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain. 2002 Dec;125(Pt 12):2591-625.[Abstract][Full Text]
115. Van Sorge NM, van der Pol WL, Jansen MD, et al. Pathogenicity of anti-ganglioside antibodies in the Guillain-Barré syndrome. Autoimmun Rev. 2004 Feb;3(2):61-8.[Abstract]
116. Hadden RD, Cornblath DR, Hughes RA, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Ann Neurol. 1998 Nov;44(5):780-8.[Abstract]
117. Rajabally YA, Durand MC, Mitchell J, et al. Electrophysiological diagnosis of Guillain-Barré syndrome subtype: could a single study suffice? J Neurol Neurosurg Psychiatry. 2015 Jan;86(1):115-9.[Abstract]
118. Ibrahim J, Grapperon AM, Manfredonia F, et al. Serial electrophysiology in Guillain-Barré syndrome: a retrospective cohort and case-by-case multicentre analysis. Acta Neurol Scand. 2018 Mar;137(3):335-40.[Abstract]
119. Uncini A, Kuwabara S. The electrodiagnosis of Guillain-Barré syndrome subtypes: where do we stand? Clin Neurophysiol. 2018 Dec;129(12):2586-93.[Abstract]
120. Wong AH, Umapathi T, Nishimoto Y, et al. Cytoalbuminologic dissociation in Asian patients with Guillain-Barré and Miller Fisher syndromes. J Peripher Nerv Syst. 2015 Mar;20(1):47-51.[Abstract]
121. DiCapua DB, Lakraj AA, Nowak RJ, et al. Relationship between cerebrospinal fluid protein levels and electrophysiologic abnormalities in Guillain-Barré syndrome. J Clin Neuromuscul Dis. 2015 Dec;17(2):47-51.[Abstract]
122. Lavi R, Yarnitsky D, Rowe JM, et al. Standard vs atraumatic Whitacre needle for diagnostic lumbar puncture: a randomized trial. Neurology. 2006 Oct 24;67(8):1492-4.[Abstract]
123. Arendt K, Demaerschalk BM, Wingerchuk DM, et al. Atraumatic lumbar puncture needles: after all these years, are we still missing the point? Neurologist. 2009 Jan;15(1):17-20.[Abstract]
124. Nath S, Koziarz A, Badhiwala JH, et al. Atraumatic versus conventional lumbar puncture needles: a systematic review and meta-analysis. Lancet. 2018 Mar 24;391(10126):1197-204.[Abstract]
125. Rochwerg B, Almenawer SA, Siemieniuk RAC, et al. Atraumatic (pencil-point) versus conventional needles for lumbar puncture: a clinical practice guideline. BMJ. 2018 May 22;361:k1920.[Abstract][Full Text]
126. Ahmed SV, Jayawarna C, Jude E. Post lumbar puncture headache: diagnosis and management. Postgrad Med J. 2006 Nov;82(973):713-6.[Abstract][Full Text]
127. Arevalo-Rodriguez I, Ciapponi A, Roqué i Figuls M, et al. Posture and fluids for preventing post-dural puncture headache. Cochrane Database Syst Rev. 2016 Mar 7;(3):CD009199.[Abstract][Full Text]
128. Lawn ND, Fletcher DD, Henderson RD, et al. Anticipating mechanical ventilation in Guillain-Barré syndrome. Arch Neurol. 2001 Jun;58(6):893-8.[Abstract][Full Text]
129. Sundar U, Abraham E, Gharat A, et al. Neuromuscular respiratory failure in Guillain-Barré syndrome: evaluation of clinical and electrodiagnostic predictors. J Assoc Physicians India. 2005 Sep;53:764-8.[Abstract]
130. Sharshar T, Chevret S, Bourdain F, et al. Early predictors of mechanical ventilation in Guillain-Barré syndrome. Crit Care Med. 2003 Jan;31(1):278-83.[Abstract]
131. Green C, Baker T, Subramaniam A. Predictors of respiratory failure in patients with Guillain-Barré syndrome: a systematic review and meta-analysis. Med J Aust. 2018 Mar 5;208(4):181-8.[Abstract]
132. Busl KM, Fried H, Muehlschlegel S, et al. Guidelines for neuroprognostication in adults with Guillain-Barré syndrome. Neurocrit Care. 2023 Jun;38(3):564-83.[Abstract][Full Text]
133. Doets AY, Walgaard C, Lingsma HF, et al. International validation of the Erasmus Guillain-Barré Syndrome Respiratory Insufficiency Score. Ann Neurol. 2022 Apr;91(4):521-31.[Abstract][Full Text]
134. Hiraga A, Kuwabara S. Early prediction of prognosis in Guillain-Barré syndrome. Lancet Neurol. 2007 Jul;6(7):572-3.[Abstract]
135. Yoshikawa K, Kuwahara M, Morikawa M, et al. Varied antibody reactivities and clinical relevance in anti-GQ1b antibody-related diseases. Neurol Neuroimmunol Neuroinflamm. 2018 Nov;5(6):e501.[Abstract][Full Text]
136. Oomes PG, van der Meché FG, Kleyweg RP. Liver function disturbances in Guillain-Barré syndrome: a prospective longitudinal study in 100 patients. Dutch Guillain-Barré Study Group. Neurology. 1996 Jan;46(1):96-100.[Abstract]
137. Durand MC, Porcher R, Orlikowski D, et al. Clinical and electrophysiological predictors of respiratory failure in Guillain-Barré syndrome: a prospective study. Lancet Neurol. 2006 Dec;5(12):1021-8.[Abstract]
138. Gorson KC, Ropper AH, Muriello MA, et al. Prospective evaluation of MRI lumbosacral nerve root enhancement in acute Guillain-Barré syndrome. Neurology. 1996 Sep;47(3):813-7.[Abstract]
139. Berciano J, Sedano MJ, Pelayo-Negro AL, et al. Proximal nerve lesions in early Guillain-Barré syndrome: implications for pathogenesis and disease classification. J Neurol. 2017 Feb;264(2):221-36.[Abstract]
140. Razali SNO, Arumugam T, Yuki N, et al. Serial peripheral nerve ultrasound in Guillain-Barré syndrome. Clin Neurophysiol. 2016 Feb;127(2):1652-6.[Abstract]
141. Ropper AH. The Guillain-Barré syndrome. N Engl J Med. 1992;326:1130-1136.[Abstract]
142. Wakerley BR, Yuki N. Polyneuritis cranialis: oculopharyngeal subtype of Guillain-Barré syndrome. J Neurol. 2015 Sep;262(9):2001-12.[Abstract]
143. Uncini A, Notturno F, Kuwabara S. Hyper-reflexia in Guillain-Barré syndrome: systematic review. J Neurol Neurosurg Psychiatry. 2020 Mar;91(3):278-84.[Abstract]
144. Fuller GN, Jacobs JM, Lewis PD, et al. Pseudoaxonal Guillain-Barré syndrome: severe demyelination mimicking axonopathy. A case with pupillary involvement. J Neurol Neurosurg Psychiatry. 1992 Nov;55(11):1079-83.[Abstract][Full Text]
145. Rougé A, Lemarié J, Gibot S, et al. Long-term impact after fulminant Guillain-Barré syndrome, case report and literature review. Int Med Case Rep J. 2016;9:357-63.[Abstract][Full Text]
146. Thomas PD. The differential diagnosis of fixed dilated pupils: a case report and review. Crit Care Resusc. 2000 Mar;2(1):34-7.[Abstract]
147. van den Berg B, Walgaard C, Drenthen J, et al. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014 Aug;10(8):469-82.[Abstract][Full Text]
148. Soar J, Böttiger BW, Carli P, et al. European Resuscitation Council guidelines 2021: adult advanced life support. Resuscitation. 2021 Apr;161:115-51.[Abstract][Full Text]
149. Colquhoun MC, Handley AJ, Evans TR. ABC of resuscitation. 5th ed. London: BMJ Publishing Group; 2004.
150. Chrimes N, Higgs A, Hagberg CA, et al. Preventing unrecognised oesophageal intubation: a consensus guideline from the Project for Universal Management of Airways and international airway societies. Anaesthesia. 2022 Dec;77(12):1395-415. [Abstract][Full Text]
151. Kesner VG, Oh SJ, Dimachkie MM, et al. Lambert-Eaton myasthenic syndrome. Neurol Clin. 2018 May;36(2):379-94.[Abstract][Full Text]
152. Ginsberg L. Vasculitis and the peripheral nervous system. Rheumatology (Oxford). 2020 May 1;59(suppl 3):iii55-59.[Abstract]
153. Rauer S, Kastenbauer S, Hofmann H, et al. Guidelines for diagnosis and treatment in neurology - Lyme neuroborreliosis. Ger Med Sci. 2020;18:Doc03.[Abstract][Full Text]
154. Thakkar JP, Kumthekar P, Dixit KS, et al. Leptomeningeal metastasis from solid tumors. J Neurol Sci. 2020 Apr 15;411:116706.[Abstract]
155. Le Rhun E, Weller M, van den Bent M, et al. Leptomeningeal metastasis from solid tumours: EANO-ESMO clinical practice guideline for diagnosis, treatment and follow-up. ESMO Open. 2023 Oct;8(5):101624.[Abstract][Full Text]
156. Gabbai AA, Castelo A, Oliveira AS. HIV peripheral neuropathy. Handb Clin Neurol. 2013;115:515-29.[Abstract]
157. Ferrari S, Vento S, Monaco S, et al. Human immunodeficiency virus-associated peripheral neuropathies. Mayo Clin Proc. 2006 Feb;81(2):213-9.[Abstract][Full Text]
158. Sejvar JJ, Kohl KS, Gidudu J, et al. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011 Jan 10;29(3):599-612.[Full Text]
159. Fross RD, Daube JR. Neuropathy in the Miller Fisher syndrome: clinical and electrophysiologic findings. Neurology. 1987 Sep;37(9):1493-8.[Abstract]
160. Van den Bergh PY, Piéret F. Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2004 Apr;29(4):565-74.[Abstract]
161. Hughes RA, Newsom-Davis JM, Perkin GD, et al. Controlled trial of prednisolone in acute polyneuropathy. Lancet. 1978;2:750-753.[Abstract]
162. Walgaard C, Lingsma HF, Ruts L, et al. Early recognition of poor prognosis in Guillain-Barre syndrome. Neurology. 2011 Mar 15;76(11):968-75.[Abstract][Full Text]
163. Doets AY, Lingsma HF, Walgaard C, et al. Predicting outcome in Guillain-Barré syndrome: international validation of the Modified Erasmus GBS Outcome Score. Neurology. 2022 Feb 1;98(5):e518-32.[Abstract][Full Text]
164. Walgaard C, Lingsma HF, Ruts L, et al. Prediction of respiratory insufficiency in Guillain-Barré syndrome. Ann Neurol. 2010 Jun;67(6):781-7.[Abstract]
165. Hughes RA, Wijdicks EF, Benson E, et al; Multidisciplinary Consensus Group. Supportive care for patients with Guillain-Barré syndrome. Arch Neurol. 2005 Aug;62(8):1194-8.[Abstract][Full Text]
166. Soar J, Böttiger BW, Carli P, et al. European Resuscitation Council Guidelines 2021: Adult advanced life support. Resuscitation. 2021 Apr;161:115-51.[Abstract][Full Text]
167. Soar J, Böttiger BW, Carli P, et al. European Resuscitation Council guidelines 2021: adult advanced life support. Resuscitation. 2021 Apr;161:115-51.[Abstract][Full Text]
168. Truax B. Autonomic disturbances in Guillain-Barré syndrome. Semin Neurol. 1984;4(4):462-8.
169. Zochodne DW. Autonomic involvement in Guillain-Barré syndrome: a review. Muscle Nerve. 1994 Oct;17(10):1145-55.[Abstract]
170. Burns TM, Lawn ND, Low PA, et al. Adynamic ileus in severe Guillain-Barré syndrome. Muscle Nerve. 2001 Jul;24(7):963-5.[Abstract]
171. Alessandro L, Castiglione JI, Brand P, et al. Treatment-related fluctuations in Guillain-Barré syndrome: clinical features and predictors of recurrence. Arq Neuropsiquiatr. 2022 May;80(5):516-22.[Abstract][Full Text]
172. Walgaard C, Jacobs BC, Lingsma HF, et al. Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2021 Apr;20(4):275-83.[Abstract]
173. Tavee J, Brannagan TH 3rd, Lenihan MW, et al. Updated consensus statement: intravenous immunoglobulin in the treatment of neuromuscular disorders report of the AANEM ad hoc committee. Muscle Nerve. 2023 Oct;68(4):356-74.[Abstract]
174. Hughes RA, Wijdicks EF, Barohn R, et al. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2003 Sep 23;61(6):736-40.[Abstract][Full Text]
175. Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol. 2017 Mar;139(3s):S1-46.[Abstract][Full Text]
176. Hughes RA, Brassington R, Gunn AA, et al. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2016 Oct 24;(10):CD001446.[Abstract][Full Text]
177. Guzey Aras Y, Tanik O, Dogan Güngen B, et al. Patient characteristics and the effects of intravenous immunoglobulin in patients with Guillain-Barre syndrome. Ideggyogy Sz. 2016 Nov 30;69(11-12):389-95.[Abstract]
178. The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol. 1997 Mar;41(3):298-306.[Abstract]
179. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol. 1987 Dec;22(6):753-61.[Abstract]
180. Osterman PO, Fagius J, Lundemo G, et al. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet. 1984 Dec 8;2(8415):1296-9.[Abstract]
181. McKhann GM, Griffin JW, Cornblath DR, et al. Plasmapheresis and Guillain-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol. 1988 Apr;23(4):347-53.[Abstract]
182. Hughes RA, Swan AV, Raphael JC, et al. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain. 2007 Sep;130(Pt 9):2245-57.[Abstract]
183. Khan F, Amatya B. Rehabilitation interventions in patients with acute demyelinating inflammatory polyneuropathy: a systematic review. Eur J Phys Rehabil Med. 2012 Sep;48(3):507-22.[Abstract][Full Text]
184. Motamed-Gorji N, Matin N, Tabatabaie O, et al. Biological drugs in Guillain-Barré syndrome: an update. Curr Neuropharmacol. 2017;15(7):938-50.[Abstract][Full Text]
185. Misawa S, Kuwabara S, Sato Y, et al. Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial. Lancet Neurol. 2018 Jun;17(6):519-29.[Abstract]
186. Kuwabara S, Kusunoki S, Kuwahara M, et al. Efficacy and safety of eculizumab in Guillain-Barré syndrome: a phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial. J Peripher Nerv Syst. 2024 Sep;29(3):339-49.[Abstract][Full Text]
187. Doets AY, Hughes RA, Brassington R, et al. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2020 Jan 25;1(1):CD008630.[Abstract][Full Text]
188. ClinicalTrials.gov. A study of imlifidase in patients with Guillain-Barré syndrome. Sep 2021 [internet publication].[Full Text]
189. Rostaing L, Noble J, Malvezzi P, et al. Imlifidase therapy: exploring its clinical uses. Expert Opin Pharmacother. 2023 Feb;24(2):259-65.[Abstract]
190. Fletcher DD, Lawn ND, Wolter TD, et al. Long-term outcome in patients with GBS requiring mechanical ventilation. Neurology. 2000 Jun 27;54(12):2311-5.[Abstract]
191. Hadden RD, Karch H, Hartung HP, et al. Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology. 2001;56:758-765.[Abstract]
192. Chiò A, Cocito D, Leone M, et al; Piemonte and Valle d'Aosta Register for Guillain-Barré Syndrome. Guillain-Barré Syndrome: a prospective, population-based incidence and outcome survey. Neurology. 2003 Apr 8;60(7):1146-50.[Abstract]
193. Stewart GJ, Pollard JD, McLeod JG, et al. Calcium homeostasis in immobilization: an example of resorptive hypercalcinuria. N Engl J Med. 1982 May 13;306(19):1136-40.[Abstract]
194. Meythaler JM, Korkor AB, Nanda T, et al. Immobilization hypercalcemia associated with Landry-Guillain-Barré syndrome. Successful therapy with combined calcitonin and etidronate. Arch Intern Med. 1986 Aug;146(8):1567-71.[Abstract]
195. Cano-Torres EA, González-Cantú A, Hinojosa-Garza G, et al. Immobilization induced hypercalcemia. Clin Cases Miner Bone Metab. 2016 Jan-Apr;13(1):46-7.[Abstract][Full Text]
196. National Institute for Health and Care Excellence. Urinary incontinence in neurological disease: assessment and management. Oct 2023 [internet publication].[Full Text]
197. Emmanuel AV, Shand AG, Kamm MA. Erythromycin for the treatment of chronic intestinal pseudo-obstruction: description of six cases with a positive response. Aliment Pharmacol Ther. 2004 Mar 15;19(6):687-94.[Abstract]
198. Ponec RJ, Saunders MD, Kimmey MB. Neostigmine for the treatment of acute colonic pseudo-obstruction. N Engl J Med. 1999 Jul 15;341(3):137-41.[Abstract][Full Text]
